Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Comoros Technology Digest.
Press releases published on May 12, 2025
Paytronix Upgrades In-App Navigation for Guests with Interstitials, Deep Linking Messages
GlobeNewswire
·
May 12, 2025
NEWTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Paytronix, the leader in guest engagement for restaurants and convenience stores, today announced the launch of two new features to its branded mobile app: interstitial messages and deep linking push and pull …
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
GlobeNewswire
·
May 12, 2025
BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the successful completion of the dose optimization of its …
ASUS Republic of Gamers Strengthens Partnership with Team NRG
GlobeNewswire
·
May 12, 2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- ASUS Republic of Gamers (ROG) and NRG today announced the expansion of their partnership. NRG, an American esports team, will benefit from a full range of ROG laptops, desktops, and handheld gaming devices — …
ALL4 Mining Launches Revolutionary Cloud Mining Platform to Maximize Profits on Bitcoin (BTC), Dogecoin (DOGE) and Ripple (XRP)
GlobeNewswire
·
May 12, 2025
Miami, FL, May 12, 2025 (GLOBE NEWSWIRE) -- As the cryptocurrency market gains new momentum in 2025, ALL4 Mining has become the focus of media attention by announcing the launch of its groundbreaking cloud mining platform, which is designed to help …
Advent Technologies Announces Dr. Ryan Pavlicek as General Manger of Livermore Facility
GlobeNewswire
·
May 12, 2025
LIVERMORE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Advent Technologies Holdings, Inc. (NASDAQ: ADN) ("Advent "or the "Company"), an innovation-driven leader in the fuel cell and hydrogen technology sector, is pleased to announce that Dr. Ryan Pavlicek has …
Orbit International Corp. Reports 2025 First Quarter Results
GlobeNewswire
·
May 12, 2025
First Quarter 2025 Net Loss of $2,152,000 ($0.65 loss per share) v. Net Loss of $751,000 ($0.22 loss per share) in Prior Year Comparable Period First Quarter 2025 EBITDA, as adjusted, was a loss of $1,949,000 ($0.59 loss per share) v. loss of $551,000 ($0. …
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
GlobeNewswire
·
May 12, 2025
PALM BEACH, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial Intelligence (AI) is becoming more essential in the medical markets every day, it seems. AI algorithms have demonstrated the capability to analyze vast amounts …
Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial
GlobeNewswire
·
May 12, 2025
Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the “MIRACLE” trial) evaluating Annamycin for the treatment of R/R …
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP
GlobeNewswire
·
May 12, 2025
May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 …
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
GlobeNewswire
·
May 12, 2025
LEIDEN, Netherlands …
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
GlobeNewswire
·
May 12, 2025
Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol population (p=0.04). Significantly fewer …
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
GlobeNewswire
·
May 12, 2025
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from its First-In- …
Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement
GlobeNewswire
·
May 12, 2025
Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today addresses frequently asked stockholder …
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
May 12, 2025
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities …
nuVizz and Ford Motor Company to Share Keys to 96% Parts Delivery Success at Home Delivery World
GlobeNewswire
·
May 12, 2025
ATLANTA, May 12, 2025 (GLOBE NEWSWIRE) -- nuVizz, a leading innovator in last-mile transportation management solutions (TMS), will present alongside Ford Motor Company at Home Delivery World 2025, one of North America’s premier logistics and supply chain …
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
GlobeNewswire
·
May 12, 2025
WARRINGTON, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
GlobeNewswire
·
May 12, 2025
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study Designed to Broaden Patient and Healthcare Community …
Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis
GlobeNewswire
·
May 12, 2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today …
Belite Bio to Participate in Four Upcoming Investor Conferences
GlobeNewswire
·
May 12, 2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical …
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 12, 2025
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB …